QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)

Revance Therapeutics (RVNC) Competitors

$5.66
-0.04 (-0.70%)
(As of 02/28/2024 ET)

RVNC vs. ABUS, AMRN, KALV, NRIX, PAHC, CDMO, LBPH, TERN, NKTX, and JANX

Should you be buying Revance Therapeutics stock or one of its competitors? The main competitors of Revance Therapeutics include Arbutus Biopharma (ABUS), Amarin (AMRN), KalVista Pharmaceuticals (KALV), Nurix Therapeutics (NRIX), Phibro Animal Health (PAHC), Avid Bioservices (CDMO), Longboard Pharmaceuticals (LBPH), Terns Pharmaceuticals (TERN), Nkarta (NKTX), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical preparations" industry.

Revance Therapeutics vs.

Arbutus Biopharma (NASDAQ:ABUS) and Revance Therapeutics (NASDAQ:RVNC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, community ranking, risk, analyst recommendations and valuation.

Revance Therapeutics has a net margin of -193.42% compared to Revance Therapeutics' net margin of -339.32%. Revance Therapeutics' return on equity of -56.45% beat Arbutus Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Arbutus Biopharma-339.32% -56.45% -41.81%
Revance Therapeutics -193.42%-903.28%-59.67%

In the previous week, Arbutus Biopharma and Arbutus Biopharma both had 8 articles in the media. Revance Therapeutics' average media sentiment score of 0.41 beat Arbutus Biopharma's score of 0.32 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arbutus Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Revance Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Arbutus Biopharma received 29 more outperform votes than Revance Therapeutics when rated by MarketBeat users. Likewise, 70.64% of users gave Arbutus Biopharma an outperform vote while only 63.84% of users gave Revance Therapeutics an outperform vote.

CompanyUnderperformOutperform
Arbutus BiopharmaOutperform Votes
421
70.64%
Underperform Votes
175
29.36%
Revance TherapeuticsOutperform Votes
392
63.84%
Underperform Votes
222
36.16%

Arbutus Biopharma has higher earnings, but lower revenue than Revance Therapeutics. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arbutus Biopharma$39.02M12.38-$69.46M-$0.46-6.26
Revance Therapeutics$132.57M3.75-$356.42M-$4.99-1.13

39.5% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 93.3% of Revance Therapeutics shares are owned by institutional investors. 5.4% of Arbutus Biopharma shares are owned by company insiders. Comparatively, 3.6% of Revance Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Arbutus Biopharma presently has a consensus target price of $6.00, indicating a potential upside of 108.33%. Revance Therapeutics has a consensus target price of $18.11, indicating a potential upside of 219.98%. Given Arbutus Biopharma's higher possible upside, analysts plainly believe Revance Therapeutics is more favorable than Arbutus Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arbutus Biopharma
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Revance Therapeutics
0 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

Arbutus Biopharma has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500.

Summary

Arbutus Biopharma beats Revance Therapeutics on 11 of the 17 factors compared between the two stocks.


Get Revance Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVNC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RVNC vs. The Competition

MetricRevance TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$497.01M$6.52B$4.96B$7.45B
Dividend YieldN/A2.64%2.90%3.88%
P/E Ratio-1.1310.36225.8416.90
Price / Sales3.75171.933,032.6664.65
Price / CashN/A19.7194.9854.63
Price / Book37.734.814.474.66
Net Income-$356.42M$152.42M$112.56M$210.60M
7 Day Performance5.40%6.86%5.15%2.49%
1 Month Performance-5.03%14.30%13.01%4.77%
1 Year Performance-83.69%6.75%11.94%7.50%

Revance Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABUS
Arbutus Biopharma
2.5247 of 5 stars
$2.88
-0.7%
$6.00
+108.3%
+10.2%$482.98M$39.02M-6.2696Upcoming Earnings
Short Interest ↓
AMRN
Amarin
0.4368 of 5 stars
$1.19
-1.7%
$1.08
-9.0%
-26.6%$480.56M$369.19M-9.15365Upcoming Earnings
Gap Down
KALV
KalVista Pharmaceuticals
3.9727 of 5 stars
$13.80
-7.1%
$26.33
+90.8%
+99.7%$476.93MN/A-4.51118Short Interest ↑
NRIX
Nurix Therapeutics
3.0826 of 5 stars
$10.09
+2.2%
$22.83
+126.3%
+32.3%$493.30M$76.99M-3.81297Analyst Report
Gap Down
PAHC
Phibro Animal Health
4.3756 of 5 stars
$12.22
+1.2%
$15.33
+25.5%
-16.1%$494.91M$977.90M33.941,920Positive News
CDMO
Avid Bioservices
4.3116 of 5 stars
$7.44
-0.8%
$14.25
+91.5%
-50.2%$470.51M$149.27M-43.76365Short Interest ↑
LBPH
Longboard Pharmaceuticals
2.3668 of 5 stars
$21.16
-0.5%
$36.00
+70.1%
+366.1%$504.88MN/A-8.7432Short Interest ↑
TERN
Terns Pharmaceuticals
3.7853 of 5 stars
$7.47
-5.0%
$14.64
+96.0%
-24.0%$461.57M$1M-5.8846
NKTX
Nkarta
2.139 of 5 stars
$10.32
-4.8%
$14.80
+43.4%
+168.5%$506.40MN/A-4.13167News Coverage
Gap Down
JANX
Janux Therapeutics
0.6984 of 5 stars
$9.96
+5.6%
$28.33
+184.5%
+198.6%$459.83M$8.47M-6.7364Analyst Report
Analyst Revision
News Coverage
Gap Up
High Trading Volume

Related Companies and Tools

This page (NASDAQ:RVNC) was last updated on 2/28/2024 by MarketBeat.com Staff